atopic dermatitis
Conditions
Interventions
Dose reduction group:None
Extended dosing interval group:None
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with AD diagnosed according to the Hanifin & Rajka diagnostic criteria; 2. Baseline Scoring of Atopic Dermatitis (SCORAD) score >= 25; 3. Received abrocitinib at a starting dose of 100 mg/day; 4. After achieving an adequate response, agreed to attempt dose reduction based on shared decision-making between physician and patient; 5. Dose reduction follow-up period >= 24 weeks, with complete records of all scores (SCORAD, EASI, NRS, and IGA) at follow-up time points.
Exclusion criteria
Exclusion criteria: 1. Presence of other active skin diseases besides AD, or concurrent conditions affecting blood cell counts (infection, surgery, malignancy); 2. Presence of secondary infection, ulceration, or other skin lesions at the affected site that may interfere with the evaluation of treatment efficacy; 3. Incomplete clinical data, including SCORAD scores, EASI scores, and other relevant assessments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema area and severity index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Numerical Rating Scale; | — |
Countries
China
Contacts
Public ContactZhiqiang Song
The First Affiliated Hospital of Army Medical University
Outcome results
None listed